The company believes that its technology will enable the development of bioengineered sensors that 'become one' with the body to detect and continuously transmit actionable, medical-grade data for personal and medical use. Profusa has stated that it is dedicated to becoming a leader in the development of real-time biosensors that provide insight into a person's overall health status. Biolinq is developing a continuous glucose monitor (CGM) patch, a wirelessly enabled electrochemical biosensor patch technology that is initially designed to simplify diabetes management and improve the CGM patient experience by removing the need for injections. The biosensor chips developed by the EFPL’s scientists are able to assess the homeostasis of individuals and measure more accurately than traditional methods the concentration in the body of an active agent coming from an administered drug, which could prove beneficial in the development of a drug. In 2015, Pierre Fabre Médicament (PFM) and the Swiss Federal Institute of Technology in Lausanne (EPFL) agreed to a scientific collaboration on the use of biosensor chips developed by the EPFL in clinical studies conducted by PFM. The advances have attracted multiple companies into the field. These have moved on from simple chemical detectors to implantable or wearable devices that can detect biomarker, disease or drug levels. It is expected that the battery-free and wireless ultra-small implantable medical devices developed by the company will enable new classes of biosensors to monitor the condition of tissues and organs, as well as new treatment devices by providing stimulation to nerves and muscles.īiosensors are increasing in complexity as technology advances. The collaboration will allow Astellas to explore new methods of delivering diagnostics and therapies that work alongside traditional treatments as well as new treatment methods, as the company looks to create revenue streams outside its core products.Ĭonventional implantable medical devices have faced challenges related to their size, imposed by the need for batteries, wires and large electronic circuits. The research will be based on the work of Iota Biosciences, which has created devices a few millimetres long that can be implanted almost anywhere in the body, powered by ultrasound and free of batteries. The collaboration will enable Astellas and iota to design specifications of implantable medical devices and conduct preclinical studies for several diseases with high unmet medical needs. The collaboration will allow Astellas to explore new methods of delivering diagnostics and therapies while increasing product diversity.Īstellas Pharma and US startup iota Biosciences' joint R&D development will aim to explore biosensing and treatment measures using ultra-small implantable medical devices.The joint venture will enable iota Biosciences to develop new classes of implantable biosensors.Astellas Pharma and iota Biosciences' research collaboration reflects the growing interest in novel biosensors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |